rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
10
|
pubmed:dateCreated |
2011-5-10
|
pubmed:abstractText |
Although finasteride is recognized for its role as a chemopreventive agent for prostate cancer, higher grades of malignancy have been reported. It is questioned whether blocking of testosterone conversion to dihydrotestosterone (DHT) by finasteride in prostate tissue will change expression of androgen receptor (AR). Therefore, this study evaluated the effects of finasteride on AR expression in prostate tissue and in the LNCaP cell line.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
1097-0045
|
pubmed:author |
|
pubmed:copyrightInfo |
Copyright © 2011 Wiley-Liss, Inc.
|
pubmed:issnType |
Electronic
|
pubmed:volume |
71
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1115-21
|
pubmed:meshHeading |
pubmed-meshheading:21557276-5-alpha Reductase Inhibitors,
pubmed-meshheading:21557276-Aged,
pubmed-meshheading:21557276-Androgens,
pubmed-meshheading:21557276-Cells, Cultured,
pubmed-meshheading:21557276-Dihydrotestosterone,
pubmed-meshheading:21557276-Finasteride,
pubmed-meshheading:21557276-Humans,
pubmed-meshheading:21557276-Immunohistochemistry,
pubmed-meshheading:21557276-Male,
pubmed-meshheading:21557276-Prostate,
pubmed-meshheading:21557276-Prostatic Hyperplasia,
pubmed-meshheading:21557276-Receptors, Androgen,
pubmed-meshheading:21557276-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:21557276-Testosterone,
pubmed-meshheading:21557276-Up-Regulation
|
pubmed:year |
2011
|
pubmed:articleTitle |
Finasteride upregulates expression of androgen receptor in hyperplastic prostate and LNCaP cells: implications for chemoprevention of prostate cancer.
|
pubmed:affiliation |
Department of Urology, National Taiwan University Hospital and National Taiwan University, College of Medicine, Taipei, Taiwan.
|
pubmed:publicationType |
Journal Article
|